Cervical Cancer News and Research

RSS

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

African-American women have delay in follow-up after finding suspicious breast abnormality, says study

A new analysis has identified a significant delay in follow-up times among African-American women after the finding of a suspicious breast abnormality. Published in the December 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that African-American women may face obstacles to receiving appropriate breast cancer-related care.

27 Oct 2009

AJPM article calls for increased effectiveness research on clinical preventive services for adolescents

Too little attention is paid to improving the delivery of clinical preventive services to adolescents by addressing problems unique to that population, says a new study commissioned by Partnership for Prevention.

27 Oct 2009

Vaccination rates need improvement; racial and ethnic disparities in vaccination coverage

More teenagers are being vaccinated against human papillomavirus (HPV), meningococcal meningitis and pertussis (whooping cough), though the rates are still too low, according to recently released government data and a panel of experts convened by the National Foundation for Infectious Diseases (NFID).

27 Oct 2009

Comprehensive, risk-based screening guidelines for breast, cervical and colorectal cancers

Drawing on years of experience in cancer research and patient care, The University of Texas M. D. Anderson Cancer Center released today the most comprehensive, risk-based screening guidelines publicly available to date for breast, cervical and colorectal cancers.

27 Oct 2009

Researchers identify how Tissue Factor contributes to cancer growth

A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists.

27 Oct 2009

PAF board member meets First Lady to dicuss denial of health insurance due to pre-existing conditions

The Patient Advocate Foundation (PAF) -- a national non-profit organization providing patient services to tens of thousands of patients every year who are unable to obtain access to care because of financial or insurance denials -- is pleased to announce that PAF Executive Board Member Venus Gines, founder and CEO of Dia de la Mujer Latina(TM) Inc (Day of the Latin American Woman), provided first-hand testimony today to First Lady Michelle Obama regarding her own and other patients' experiences in being denied health insurance due to pre-existing conditions, and the need to protect patients against such discrimination under healthcare reform.

24 Oct 2009

FMWC partners with SOGC and SCC to launch Pap test campaign

The Federation of Medical Women of Canada (FMWC) has joined forces with the Society of Obstetricians and Gynaecologists of Canada (SOGC) and the Society of Canadian Colposcopists (SCC) to launch this year's Pap test campaign during Cervical Cancer Awareness Week. Together, we hope to increase the scope, reach and impact of the campaign. With this collaborative effort, we aim to provide more Pap tests and deal with abnormal results in a more expeditious manner.

22 Oct 2009

Merck's sales increases by 2% in third quarter 2009

Merck & Co., Inc. today announced financial results for the third quarter of 2009. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the quarter of $0.90, which excludes a $1.7 billion after-tax gain from the sale of the company's interest in Merial Limited as well as restructuring charges and pre-closing merger-related expenses. Third-quarter GAAP EPS was $1.61.

22 Oct 2009

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider.

22 Oct 2009

GlaxoSmithKline's CERVARIX recommended by CDC for protection against cervical cancer

GlaxoSmithKline announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) recommended that CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] be given to girls and young women to protect against cervical pre-cancers and cervical cancer caused by oncogenic HPV 16 and 18.

22 Oct 2009

Inovio Biomedical highlights its advances in SynCon DNA vaccines

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced that Dr. David B. Weiner, Chairman of Inovio’s Scientific Advisory Board, highlighted advances in electroporation-delivered SynCon™ DNA vaccines compared to other leading vaccine technologies at the AIDS Vaccine 2009 Conference being held this week in Paris, France.

21 Oct 2009

Alberta revises its cervical cancer screening guideline

Alberta has revised its Cervical Cancer Screening Clinical Practice Guideline (CPG) based on new technologies and epidemiologic evidence from Alberta and internationally.

20 Oct 2009

Health Discovery Corporation granted additional patents for Recursive Feature Elimination using Support Vector Machines

Health Discovery Corporation is pleased to announce numerous additional issued patents and Notices of Allowance since its last press release describing its intellectual property portfolio. The Company now has a total of 37 issued patents, 4 Notices of Allowance and 30 pending patent applications.

20 Oct 2009

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

The FDA today approved Cervarix, a new vaccine to prevent cervical cancer and precancerous lesions caused by human papillomavirus (HPV) types 16 and 18. The vaccine is approved for use in girls and women ages 10 years through 25 years.

19 Oct 2009

Hologic opens new facility in Hong Kong

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the opening of its new Asia Pacific regional offices and the Hologic Asia Pacific Center for Health Sciences Education in Hong Kong.

From Hologic, Inc. 19 Oct 2009

Yashoda Cancer Institute in India to expand use of Varian Medical Systems' RapidArc radiotherapy

A hospital that is using RapidArc radiotherapy to treat cancers of the head & neck and cervix is announcing it will be expanding its use for treatment of other cancers. Yashoda Cancer Institute in Hyderabad has found it can deliver image-guided, intensity modulated radiotherapy (IMRT) faster and more precisely using the RapidArc technology from Varian Medical Systems.

19 Oct 2009

Chinese SFDA approves China Medical Technologies' SPR System

China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its SPR- based analysis system (the "SPR System") from the State Food and Drug Administration of China (the "SFDA").

19 Oct 2009

Majority of girls and young women well aware of HPV vaccine's benefits and limitations

Contrary to concerns that the human papillomavirus vaccine might promote promiscuity, a national survey of girls and young women found that the majority of respondents did not believe the HPV vaccine protected them against other sexually transmitted infections.

19 Oct 2009

Phase I clinical study of PENNVAX-B preventive DNA vaccine using electroporation technology

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, and the HIV Vaccine Trials Network (HVTN) announced today the initiation of a phase I clinical study of Inovio’s PENNVAX-B preventive DNA vaccine delivered using its proprietary electroporation technology.

19 Oct 2009

GlaxoSmithKline receives FDA approval for cervical cancer vaccine

GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10-25).

19 Oct 2009

Cervical Cancer News and Research

Further Reading

African-American women have delay in follow-up after finding suspicious breast abnormality, says study

AJPM article calls for increased effectiveness research on clinical preventive services for adolescents

Vaccination rates need improvement; racial and ethnic disparities in vaccination coverage

Comprehensive, risk-based screening guidelines for breast, cervical and colorectal cancers

Researchers identify how Tissue Factor contributes to cancer growth

PAF board member meets First Lady to dicuss denial of health insurance due to pre-existing conditions

FMWC partners with SOGC and SCC to launch Pap test campaign

Merck's sales increases by 2% in third quarter 2009

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

GlaxoSmithKline's CERVARIX recommended by CDC for protection against cervical cancer

Inovio Biomedical highlights its advances in SynCon DNA vaccines

Alberta revises its cervical cancer screening guideline

Health Discovery Corporation granted additional patents for Recursive Feature Elimination using Support Vector Machines

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

Hologic opens new facility in Hong Kong

Yashoda Cancer Institute in India to expand use of Varian Medical Systems' RapidArc radiotherapy

Chinese SFDA approves China Medical Technologies' SPR System

Majority of girls and young women well aware of HPV vaccine's benefits and limitations

Phase I clinical study of PENNVAX-B preventive DNA vaccine using electroporation technology

GlaxoSmithKline receives FDA approval for cervical cancer vaccine

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News